A proposed class action filed just days ago is shaking the generic drug industry — and millions of heart patients across America may be affected. The Glenmark carvedilol lawsuit, filed August 4, 2026, in the U.S. District Court for the Eastern District of Washington, alleges that Glenmark Pharmaceuticals Inc. USA sold a generic version of the heart medication carvedilol (brand name Coreg) contaminated with a probable human carcinogen at levels exceeding FDA safety limits. With nearly 733,000 bottles already recalled and the complaint spanning 139 pages of detailed allegations, this case is rapidly emerging as one of the most significant nitrosamine drug contamination lawsuits of 2026.
What Is the Glenmark Carvedilol Lawsuit?
Washington resident Sharon Carroll filed the proposed class action against Glenmark Pharmaceuticals Inc. USA on August 4, 2026, alleging the company sold generic carvedilol tainted with the chemical compound N-Nitroso-Carvedilol I — a substance classified as a probable human carcinogen. Carroll purchased Glenmark carvedilol four times between March 2024 and July 2025 using prescriptions tied to NDC codes 68462-0164-05 and 68462-0163-05, both of which were later included in Glenmark’s recalls. The suit seeks reimbursement of purchase and replacement costs on behalf of a nationwide class of consumers who unknowingly received the contaminated medication.
The 139-page complaint asserts that Glenmark’s generic carvedilol lacked the same safety profile, strength, quality, and purity as brand-name Coreg — a legally significant claim, because generic drugs are required by law to be equivalent to their brand-name counterparts. The Glenmark carvedilol lawsuit further charges that the company failed to manufacture the drug in a current Good Manufacturing Practice (cGMP)-compliant manner, rendering the products both adulterated and misbranded under federal law. For patients relying on this medication to manage life-threatening heart conditions, those are not minor technical violations — they go to the core of what patients were promised when they filled their prescriptions. If you believe you were harmed by a contaminated pharmaceutical product, understanding how damages are calculated is a critical first step — a medical malpractice calculator can help you begin estimating potential compensation for defective drug injuries.
The Recall: Scope, Timeline, and FDA Classification
The recall that underlies the Glenmark carvedilol lawsuit is substantial in scale. According to FDA enforcement records, the recall covers 732,960 bottles across multiple strengths and package sizes, including 3.125 mg, 12.5 mg, and 25 mg tablets manufactured by Glenmark Pharmaceuticals Ltd. in India and distributed throughout the United States. Glenmark voluntarily initiated the recall on August 6 and 7, 2025, with the FDA confirming a Class II classification on August 12 and 14, 2025.
A Class II recall designation means that use of the product may cause temporary or medically reversible adverse health effects, and that the probability of serious health consequences is considered remote — but the long-term cancer risk associated with nitrosamine exposure complicates that framing significantly. Regulators consider nitrosamines to be high potency mutagenic carcinogens, meaning they can cause DNA damage with lasting consequences. The FDA has established an acceptable intake limit of 4.0 ppm for N-Nitroso-Carvedilol I; Glenmark’s product allegedly exceeded that threshold. Glenmark itself attributed the recall to its failure to control nitrite levels in excipients — the inactive ingredients used during drug manufacturing — a process failure the class action complaint says could have affected every batch or lot ever produced, not only those explicitly listed in the recall notices. You can review the FDA’s regulatory framework for drug recalls directly at FDA.gov’s drug recall information page.
Key Facts and Data: Glenmark Carvedilol Recall and Lawsuit at a Glance
| Detail | Information |
|---|---|
| Case Filed | August 4, 2026 — U.S. District Court, Eastern District of Washington |
| Lead Plaintiff | Sharon Carroll, Washington resident |
| Defendant | Glenmark Pharmaceuticals Inc. USA |
| Contaminant | N-Nitroso-Carvedilol I (probable human carcinogen) |
| FDA Acceptable Intake Limit | 4.0 ppm for N-Nitroso-Carvedilol I |
| Bottles Subject to Recall | 732,960+ bottles across multiple strengths |
| Recall Strengths | 3.125 mg, 12.5 mg, and 25 mg tablets |
| Recall Initiation Date | August 6–7, 2025 (voluntary, by Glenmark) |
| FDA Recall Classification | Class II (confirmed August 12–14, 2025) |
| FDA Generic Approval Year | 2007 (Glenmark received FDA approval to sell generic carvedilol) |
| Complaint Length | 139 pages |
These figures underscore why the Glenmark carvedilol lawsuit has attracted immediate national attention. Nearly three-quarters of a million bottles reached American consumers before the recall was triggered, and the complaint alleges the contamination problem stretches back many years — meaning patients who took this drug well before the recall window may also have been exposed.
How Nitrosamine Contamination Happens — and Why It Matters
Understanding the science behind the Glenmark carvedilol lawsuit is essential for affected patients. Nitrosamines are a class of chemical compounds that can form during the drug manufacturing process when certain active pharmaceutical ingredients react with nitrites present in inactive ingredients or manufacturing solvents. In Glenmark’s case, the complaint alleges that N-Nitroso-Carvedilol I formed precisely this way — when carvedilol reacted with nitrites in excipients during production. Critically, the suit alleges Glenmark had actual or constructive notice of the danger of nitrosamine contamination and willfully disregarded scientific and industry guidance that should have prompted corrective action years earlier.
This is not an isolated manufacturing error. Glenmark has received multiple FDA warning letters and, according to court filings, has for at least the fifth time in a year sold millions of nitrosamine-contaminated drugs. The FDA’s September 2024 Revision 2 guidance significantly expanded manufacturer testing expectations and established new analytical standards for detecting nitrosamine impurities — a regulatory framework that was publicly available and binding on Glenmark. Nitrosamines increase cancer risk when people experience long-term exposure above acceptable levels, and carvedilol is typically taken daily for years or even decades by patients managing chronic heart conditions. For context on how federal health agencies categorize and track carcinogenic exposure risks, see the CDC’s resource on occupational and chemical carcinogens.
The Broader Wave of Nitrosamine Drug Litigation in 2026
The Glenmark carvedilol lawsuit is not an isolated legal event — it is part of a sweeping and still-growing wave of mass tort litigation targeting nitrosamine contamination in generic pharmaceuticals. The pattern began with the Valsartan scandal, which ultimately resulted in a $15.26 million settlement in MDL 2875 covering Valsartan, Losartan, and Irbesartan claims. It expanded with the Zantac (ranitidine) litigation, then moved to metformin and smoking-cessation drugs. In 2026 alone, two major settlement milestones have already been reached: the $44 million Chantix class action settlement received preliminary approval on June 1, 2026, and metformin nitrosamine class action settlements with Teva and Granules/Heritage received preliminary approval on May 4, 2026, with a final approval hearing held on August 12, 2026.
These settlements demonstrate that nitrosamine contamination cases can produce significant recoveries for affected consumers — and they set important legal precedents that plaintiffs’ attorneys in the Glenmark carvedilol lawsuit will likely rely upon. The common thread across all of these cases is the same: drug manufacturers knew or should have known about the risks of nitrosamine formation, had regulatory guidance available to prevent it, and failed to act — leaving patients to unknowingly ingest probable carcinogens in medications they trusted to help them, not harm them. Understanding your legal options in a mass tort case begins with understanding what your claim may be worth; a personal injury settlement calculator can provide a preliminary framework for evaluating potential compensation. Legal precedents and statutes governing pharmaceutical liability claims are codified under federal and state law, which you can explore through Cornell Law School’s Legal Information Institute, 21 U.S.C. § 351 (Adulterated Drugs).
Who May Be Eligible to Join the Glenmark Carvedilol Lawsuit?
The proposed class action is broad by design. Any consumer in the United States who purchased Glenmark-manufactured generic carvedilol — particularly in 3.125 mg, 12.5 mg, or 25 mg tablet form — may have a basis to participate in the litigation. Carvedilol is a beta-blocker widely prescribed to treat high blood pressure, congestive heart failure, and other heart conditions, meaning millions of American patients depend on it daily. The complaint’s allegation that contamination may have affected every batch or lot ever produced — not just those in the formal recall — dramatically expands the potential class. Patients who took Glenmark carvedilol over an extended period face the greatest potential exposure to elevated nitrosamine levels, and those who have subsequently received a cancer diagnosis may have claims that extend well beyond reimbursement of purchase costs.
If you or a family member took Glenmark carvedilol and later developed cancer or another serious illness, the legal landscape of the Glenmark carvedilol lawsuit is developing rapidly, and timeliness matters. In mass tort cases, early participation in litigation can affect discovery access, settlement positioning, and claim prioritization. Documenting your prescription history, pharmacy receipts, and any medical records related to diagnoses received after taking this medication is an important first step regardless of what legal action you ultimately pursue.
Frequently Asked Questions About the Glenmark Carvedilol Lawsuit
What is the Glenmark carvedilol lawsuit about?
The Glenmark carvedilol lawsuit is a proposed class action filed August 4, 2026, in the U.S. District Court for the Eastern District of Washington. Lead plaintiff Sharon Carroll alleges that Glenmark Pharmaceuticals Inc. USA sold generic carvedilol (a heart medication also known by the brand name Coreg) contaminated with N-Nitroso-Carvedilol I — a probable human carcinogen — at levels above the FDA’s acceptable intake limit of 4.0 ppm. The suit covers a recall of 732,960+ bottles and claims the contamination may have affected all batches produced, not only recalled lots.
Is generic carvedilol currently safe to take?
Patients should not stop taking any heart medication without consulting their physician. Abruptly discontinuing a beta-blocker like carvedilol can cause serious cardiac complications. However, if you are currently taking Glenmark-manufactured carvedilol, you should contact your prescribing doctor or pharmacist immediately to determine whether your specific lot was subject to the recall and to discuss alternative medications if appropriate. The FDA recall covered 3.125 mg, 12.5 mg, and 25 mg strengths manufactured by Glenmark Pharmaceuticals Ltd. in India.
What is N-Nitroso-Carvedilol I, and why is it dangerous?
N-Nitroso-Carvedilol I is a nitrosamine impurity — a type of chemical compound that drug regulators classify as a high potency mutagenic carcinogen. It can form during pharmaceutical manufacturing when active drug compounds react with nitrites present in inactive ingredients or excipients. Long-term exposure to nitrosamines above acceptable levels increases cancer risk. The FDA has set an acceptable daily intake limit of 4.0 ppm for this specific compound; the Glenmark recall was triggered because the company’s product allegedly exceeded that limit.
How does the Glenmark carvedilol lawsuit relate to other nitrosamine drug cases like Valsartan and Zantac?
The Glenmark carvedilol lawsuit is the latest in a growing wave of mass tort litigation targeting nitrosamine contamination in generic pharmaceuticals. Previous cases — including Valsartan (settled for $15.26 million in MDL 2875), Chantix (a $44 million settlement receiving preliminary approval June 1, 2026), and metformin (settlements with Teva and Granules/Heritage receiving preliminary approval May 4, 2026) — have established legal precedents that plaintiffs’ attorneys are expected to rely upon in the Glenmark litigation. The common allegation across all these cases is that manufacturers knew or should have known about nitrosamine formation risks and failed to act.
What compensation might be available in the Glenmark carvedilol lawsuit?
Lead plaintiff Sharon Carroll is seeking reimbursement of purchase and replacement costs for carvedilol she purchased between March 2024 and July 2025. However, class members who suffered serious health consequences — including cancer diagnoses potentially linked to long-term nitrosamine exposure — may be entitled to significantly greater compensation, including damages for medical expenses, pain and suffering, and lost income. The final scope of available compensation will depend on how the litigation develops and whether a class-wide settlement or individual verdicts are ultimately reached. Each case is unique, and potential damages vary based on individual circumstances.
Disclaimer: This article is provided for general informational purposes only and does not constitute legal advice; readers should consult a licensed attorney in their jurisdiction regarding any specific legal matter or claim.
Related reading: Medical Malpractice Mediation: How It Works, What It Pays & When To Choose It (2026)
Related reading: Forceps & Vacuum Delivery Malpractice Settlement Amounts: 2026 Data, Verdicts & How Compensation Is Calculated
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.